Company Filing History:
Years Active: 2008
Title: The Innovations of Kanyawim Kirtikara
Introduction
Kanyawim Kirtikara is a notable inventor based in Pathumthani, Thailand. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that have potential applications in medicine.
Latest Patents
Kirtikara holds a patent for antituberculosis compounds, specifically Hirsutellones A, B, and C. These three new alkaloids are produced in cultures of specific fungus strains, such as BCC 2594 and BCC 7579. The Hirsutellones have demonstrated potent growth inhibitory activity against the H37Ra strain of tuberculosis, with a minimum inhibitory concentration (MIC) value of 0.78 µg/ml. Importantly, these compounds exhibit weak or no cytotoxicity to mammalian cells, suggesting their potential for safe therapeutic use. The patent also describes methods for isolating the Hirsutellones, which could be crucial for further research and development.
Career Highlights
Kanyawim Kirtikara is affiliated with the National Center for Genetic Engineering and Biotechnology, which is part of the National Science and Technology Development Agency. His work focuses on innovative solutions to combat infectious diseases, particularly tuberculosis.
Collaborations
Kirtikara has collaborated with notable colleagues in his field, including Masahiko Isaka and Nigel Leslie Hywel-Jones. These collaborations have likely contributed to the advancement of his research and the successful development of his patented compounds.
Conclusion
Kanyawim Kirtikara's work in developing Hirsutellones A, B, and C represents a significant advancement in the fight against tuberculosis. His contributions to biotechnology highlight the importance of innovation in addressing global health challenges.